- Home
- PLMR vs KNSA Comparison
PLMR vs KNSA Comparison
Compare PLMR & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLMR | KNSA |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.5B |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PLMR | KNSA |
|---|---|---|
| Price | $124.12 | $52.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $153.60 | $58.43 |
| AVG Volume (30 Days) | 174.8K | ★ 742.4K |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.04 | ★ 225.00 |
| EPS | ★ 7.17 | 0.27 |
| Revenue | ★ $875,967,000.00 | $677,564,000.00 |
| Revenue This Year | $192.25 | $37.48 |
| Revenue Next Year | $19.34 | $17.87 |
| P/E Ratio | ★ $17.58 | $71.19 |
| Revenue Growth | 58.16 | ★ 60.09 |
| 52 Week Low | $107.75 | $25.71 |
| 52 Week High | $175.85 | $54.23 |
Technical Indicators
Market Signals| Indicator | PLMR | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 66.79 |
| Support Level | $117.39 | $40.67 |
| Resistance Level | $135.64 | N/A |
| Average True Range (ATR) | 3.63 | 2.20 |
| MACD | -0.71 | 0.68 |
| Stochastic Oscillator | 5.81 | 85.60 |
Price Performance
Historical ComparisonAbout PLMR Palomar Holdings Inc.
Palomar Holdings Inc that provides property and casualty insurance products to individuals and businesses. It provides insurance products serving five categories: Earthquake, Inland Marine and Other Property, Casualty, Fronting, and Crop. Company distribute products through multiple channels, including retail agents, program administrators, wholesale brokers, and partnerships with other insurance companies. The company's Earthquake product generate high premium.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.